Natco Pharma Q3 net profit rises over two-fold to Rs 37.15 cr
New Delhi: Drug firm Natco Pharma reported over two-fold jump in consolidated net profit at Rs 37.15 crore for the third quarter ended December 2015.
The company had posted a net profit of Rs 14.34 crore during the same quarter of the previous fiscal as it was hit by a one-off item of Rs 1,513 crore paid for settlement of a legal dispute.
Net sales of the company also increased by 42.79 per cent to Rs 263.12 crore during the period under review as against Rs 184.27 crore in the same period last fiscal, Natco Pharma said in a BSE filing.
In a separate filing, the company informed that its board has recommended an interim dividend of Rs 1.25 per equity share.
[poll id=35762]
The company had posted a net profit of Rs 14.34 crore during the same quarter of the previous fiscal as it was hit by a one-off item of Rs 1,513 crore paid for settlement of a legal dispute.
Net sales of the company also increased by 42.79 per cent to Rs 263.12 crore during the period under review as against Rs 184.27 crore in the same period last fiscal, Natco Pharma said in a BSE filing.
In a separate filing, the company informed that its board has recommended an interim dividend of Rs 1.25 per equity share.
[poll id=35762]
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd